James Cavet

Most-cited papers

1. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.

   L. Nicosia, Gary J. Spencer, N. Brooks, F. Amaral +19 more

   2023Cancer Cell113 citations Open access

   Semantic Scholar

   Save

2. Tolerability and Clinical Activity of Novel First in Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

   E. Searle, James Cavet, V. Campbell, S. Knapper +16 more

   2023Blood7 citations Open access

   Semantic Scholar

   Save

3. Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

   E. Searle, V. Campbell, C. Pawlyn, C. Bygrave +13 more

   2024Blood4 citations

   Semantic Scholar

   Save

4. Fungal Blood Stream Infections (BSI) in Hematology-Oncology Patients Have Worse Outcomes Than Solid Tumour Patients

   Vismay Deshani, H. Hemat, A. Bloor, Mike Dennis +13 more

   2024Blood0 citations

   Semantic Scholar

   Save

5. Rituximab Responsive Cytopenia Following Allogeneic Stem Cell Transplantation

   John Murray, Joanita Kintu, A. Bloor, Mike Dennis +5 more

   2024Blood0 citations

   Semantic Scholar

   Save

6. Prediction Model to Evaluate Engraftment Kinetics Following Stem Cell Transplantation

   Samar Kulkarni, A. Bloor, Mike Dennis, Anna Z Castleton +10 more

   2024Blood0 citations

   Semantic Scholar

   Save

7. Predictors of Successful Allogeneic Stem Cell Donor Collection

   Samar Kulkarni, A. Bloor, Mike Dennis, A. Leather +14 more

   2024Blood0 citations

   Semantic Scholar

   Save

8. P-190 Potent pre-clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma

   Kris Frese, L. Nicosia, F. Amaral, Oliver J. Sinclair +8 more

   2023Clinical Lymphoma, Myeloma & Leukemia0 citations

   Semantic Scholar

   Save